Trial intelligence / Profile preview

Phase II study of BEBT-109 plus chemotherapy as first-line treatment for EGFR exon 20 insertion-mutant advanced NSCLC

CTR20242216Phase 2Active

Sponsor

BeBetter Med

Start

Aug 2024

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1